Therapeutic agent for fibroid lung

Abstract

Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.

1 . A substance delivery carrier comprising a retinoid as a targeting agent, wherein the carrier delivers to an extracellular matrix-producing cell in the lung. 
     
     
         2 . The carrier according to  claim 1 , wherein the retinoid comprises retinol. 
     
     
         3 . The carrier according to  claim 1 , wherein the retinoid content is 0.2-20 wt % of the carrier. 
     
     
         4 . The carrier according to  claim 1 , wherein the carrier has a form of a liposome, and the molar ratio of the retinoid to the lipid contained in the liposome is 8:1-1:4. 
     
     
         5 . A composition comprising the carrier according to  claim 1  and a drug that controls the activity or growth of the extracellular matrix-producing cell in the lung. 
     
     
         6 . The composition according to  claim 5 , wherein the drug is selected from the group consisting of: (i) an agent for inhibiting activity or production of a bioactive substance selected from the group consisting of (1) gelatinase A, (2) gelatinase B and (3) angiotensinogen, (ii) an inhibitor of cell activity, (iii) a growth inhibitor, (iv) an apoptosis-inducing agent, (v) an agent which targets at least one of extracellular matrix constituent molecules or molecules involved in the production or secretion of said extracellular matrix constituent molecules, selected from the group consisting of (1) an siRNA, (2) a ribozyme, (3) an anti-sense nucleic acid, and (4) a DNA/RNA chimeric polynucleotide, and (vi) a vector that expresses said siRNA, said ribozyme, said anti-sense nucleic acid, and/or said DNA/RNA chimeric polynucleotide. 
     
     
         7 . The composition according to  claim 6 , wherein the molecules involved in the production or secretion of the extracellular matrix constituent molecules is HSP47. 
     
     
         8 . The composition according to  claim 5 , wherein the drug and the carrier are mixed at a place of medical treatment or in its vicinity. 
     
     
         9 . A kit for preparing the composition according to  claim 5 , wherein the kit comprises one or more containers comprising singly or in combination the drug for inhibiting activity or growth of extracellular matrix-producing cells in the lung, and the retinoid.